Literature DB >> 33984280

Does systemic inflammation prompt gene therapy uveitis?

Ying Kai Chan1, Kathryn L Pepple2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33984280      PMCID： PMC8178452          DOI： 10.1016/j.ymthe.2021.05.001

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   12.910


× No keyword cloud information.
  8 in total

1.  The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.

Authors:  Ashley T Martino; Masataka Suzuki; David M Markusic; Irene Zolotukhin; Renee C Ryals; Babak Moghimi; Hildegund C J Ertl; Daniel A Muruve; Brendan Lee; Roland W Herzog
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

2.  Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery.

Authors:  Catherine Cukras; Henry E Wiley; Brett G Jeffrey; H Nida Sen; Amy Turriff; Yong Zeng; Camasamudram Vijayasarathy; Dario Marangoni; Lucia Ziccardi; Sten Kjellstrom; Tae Kwon Park; Suja Hiriyanna; J Fraser Wright; Peter Colosi; Zhijian Wu; Ronald A Bush; Lisa L Wei; Paul A Sieving
Journal:  Mol Ther       Date:  2018-07-07       Impact factor: 11.454

Review 3.  Microglia versus Monocytes: Distinct Roles in Degenerative Diseases of the Retina.

Authors:  Chen Yu; Christophe Roubeix; Florian Sennlaub; Daniel R Saban
Journal:  Trends Neurosci       Date:  2020-04-17       Impact factor: 13.837

Review 4.  Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety.

Authors:  Kirsten Bucher; Eduardo Rodríguez-Bocanegra; Daniyar Dauletbekov; M Dominik Fischer
Journal:  Prog Retin Eye Res       Date:  2020-10-15       Impact factor: 21.198

5.  Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene therapy trial.

Authors:  Alaknanda Mishra; Camasamudram Vijayasarathy; Catherine A Cukras; Henry E Wiley; H Nida Sen; Yong Zeng; Lisa L Wei; Paul A Sieving
Journal:  Mol Ther       Date:  2021-02-15       Impact factor: 12.910

6.  Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses.

Authors:  Ying Kai Chan; Sean K Wang; Colin J Chu; David A Copland; Alexander J Letizia; Helena Costa Verdera; Jessica J Chiang; Meher Sethi; May K Wang; William J Neidermyer; Yingleong Chan; Elaine T Lim; Amanda R Graveline; Melinda Sanchez; Ryan F Boyd; Thomas S Vihtelic; Rolando Gian Carlo O Inciong; Jared M Slain; Priscilla J Alphonse; Yunlu Xue; Lindsey R Robinson-McCarthy; Jenny M Tam; Maha H Jabbar; Bhubanananda Sahu; Janelle F Adeniran; Manish Muhuri; Phillip W L Tai; Jun Xie; Tyler B Krause; Andyna Vernet; Matthew Pezone; Ru Xiao; Tina Liu; Wei Wang; Henry J Kaplan; Guangping Gao; Andrew D Dick; Federico Mingozzi; Maureen A McCall; Constance L Cepko; George M Church
Journal:  Sci Transl Med       Date:  2021-02-10       Impact factor: 19.319

7.  Effects of processing conditions on stability of immune analytes in human blood.

Authors:  Andres Gottfried-Blackmore; Samuel J S Rubin; Lawrence Bai; Sheun Aluko; Yujun Yang; Walter Park; Aida Habtezion
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

8.  Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9/2020.

Authors:  Ying Kai Chan; Andrew D Dick; Sara Mary Hall; Thomas Langmann; Curtis L Scribner; Brian C Mansfield
Journal:  Transl Vis Sci Technol       Date:  2021-04-01       Impact factor: 3.283
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.